AB0329 Ultrasound 7 versus Ultrasound12 in Monitoring The Response To Adalimumab in Patients with Rheumatoid Arthritis
Authors: S. Tropea, I. De Andres, P. Santonocito, A.A. Russo, E. Battaglia
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Objectives</h3> This study aimed to assess the responsiveness of ultrasonography (US)-7 in patients with psoriasic arthritis (RA) non responders at only MTX terapy recruided with baseline ecographic positivity per disease activity. Sixty-two RA patients were recruited and followed up for 24 weeks. <h3>Methods</h3> The clinical, laboratory, and X-ray assessments, along with grayscale US (GSUS) and power Doppler US (PDUS) examinations were performed at baseline, 6, 14, and 24 weeks after adalimumab treatment GSUS for synovitis and PDUS for synovitis and paratendinitis/tenosynovitis were assessed by a semi-quantitative (0 to 3) score, while GSUS for paratendinitis/tenosynovitis and bone erosion was qualitatively assessed as absent or present (0 or 1). US scores in both 7-joint (US7) and 12-joint (US12) systems were evaluated. <h3>Results</h3> After 6, 14, and 24weeks of treatment with adalimumab, indices such as US scores in both 7-joint (US7) and 12-joint (US12) systems were evaluated. After 6, 14, and 24 weeks of treatment with adalimumab indices such as US scores, 28-joint disease activity (DAS28) score, and tender and swelling joint count were all significantly improved compared to baseline. US7 scores were significantly correlated with that of US12. Strong correlations were identified between most US7 scores with DAS28, health assessment questionnaire (HAQ), and C-reactive protein (CRP) levels. When DAS28 was used as a reference, the US7 cutoff for disease remission was less than 35 for GS+PD and also less than 29 for GS and 1 for PD, respectively <h3>Conclusions</h3> Additionally, the positive percent agreement, negative percent agreement, and overall percent agreement for GS+PD were 77.78, 76.19, and 76.67%, respectively, which were all higher than that of GS or PD. US7 may be a feasible tool to assess the therapeutic response in RA patients. <h3>References</h3> Power Doppler ultrasonographic monitoring of response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Naredo E, Moller I, Cruz A, Carmona L, Garido J. Arthritis Rheum. 2008 Aug;58(8):2248–56. doi: 10.1002/art.23682 Skeletal Radiol. 2010 May;39(5):457–65. doi: 10.1007/s00256-009-0824-5. Epub 2009 Nov 20. Semi-quantitative analysis of rheumatoid finger joint synovitis using power Doppler ultrasonography: when to perform follow-up study after treatment consisting mainly of antitumor necrosis factor alpha agent. Kamishima T, Sagawa A, Tanimura K, Shimizu M, Matsuhashi M, Shinohara M, Hagiwara H, Henmi M, Narita A, Terae S, Shirato H. Skeletal Radiol. 2010 May;39(5):457–65. doi: 10.1007/s00256-009-0824-5. Epub 2009 Nov 20. Rheumatoid hand joint synovitis: gray-scale and power Doppler US quantifications following anti-tumor necrosis factor-alpha treatment: pilot study.Ribbens C, André B, Marcelis S, Kaye O, Mathy L, Bonnet V, Beckers C, Malaise MG.Radiology. 2003 Nov;229(2):562–9. Epub 2003 Sep 11 <h3>Disclosure of Interest</h3> None declared